Study on Tepotinib and Osimertinib for Treating MET Amplified Non-Small Cell Lung Cancer After Osimertinib Relapse

Inclusion Criteria

• Have advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by lab tests, with a specific EGFR mutation.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 12 weeks.
• Have shown resistance to first-line osimertinib treatment, with documented disease progression.
• Have previously benefited from osimertinib treatment, showing either a partial or complete response, or stable disease lasting more than 6 months.
• Have only received osimertinib as the first treatment for advanced or metastatic NSCLC.
• Have MET amplification confirmed by specific tests on tumor or blood samples after progression on osimertinib.
• Provide tumor and blood samples for MET amplification testing after progression on osimertinib.
• Other criteria as defined by the study protocol may apply.

Exclusion Criteria

• Have spinal cord compression or brain metastasis unless they are not causing symptoms, are stable, or do not require steroids for at least 2 weeks before starting the study.
• Have unresolved side effects from previous cancer treatments, except for hair loss.
• Have inadequate blood, liver, or kidney function.
• Have heart problems.
• Have a history of lung diseases like interstitial lung disease or pneumonitis that required steroid treatment.
• Have high blood pressure that is not controlled to below 150/90 mmHg.
• Cannot take osimertinib for any reason.
• Other criteria as defined by the study protocol may apply.